{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T09:26:25Z","timestamp":1793179585546,"version":"4.5.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Two recent meta-analyses reported subclinical vasculitis in 22\u201323% of patients with PMR. We aimed to evaluate the prevalence, characteristics, and outcome of subclinical vasculitis among our PMR patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Consecutive patients with GCA\/PMR spectrum disease with isolated PMR symptoms who underwent FDG PET imaging between 2003 and 2020 and who were followed for \u22656\u2009months, were included retrospectively. Vasculitis was defined as FDG uptake \u2265grade 2 in any vessel.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 337 patients, of whom 31 (9%) with subclinical vasculitis. Among those with subclinical vasculitis, 21 (58%) had isolated large vessel vasculitis, 3 (10%) had isolated cranial vasculitis and 7 (23%) had both cranial and large vessel vasculitis. The glucocorticoid (GC) starting dose and GC doses during follow-up were higher in those with subclinical vasculitis until 12\u2009months after diagnosis (P\u2009&amp;lt;\u20090.001). There was no difference in the duration of GC treatment (25 vs 20\u2009months, P\u2009=\u20090.187). Cox proportional hazard regression analyses showed no difference in the proportion of patients able to stop GC (HR 0.78 [95% CI 0.49\u20131.25], P\u2009=\u20090.303) and in the proportion of patients with relapse (HR 0.82 [95%CI 0.50\u20131.36], P\u2009=\u20090.441).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Only 9% of our PMR patients had subclinical vasculitis with a predilection for large vessel vasculitis. There were no differences in relapse rate and duration of GC treatment, however, those with subclinical vasculitis received higher GC doses until 12\u2009months after diagnosis. Prospective interventional trials are needed to evaluate the outcome of PMR patients with and without subclinical vasculitis treated with a similar GC protocol.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae208","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T19:37:45Z","timestamp":1711654665000},"page":"3331-3336","source":"Crossref","is-referenced-by-count":19,"title":["Prevalence, characteristics, and outcome of subclinical vasculitis in polymyalgia rheumatica: a retrospective cohort study"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7613-4801","authenticated-orcid":false,"given":"Lien","family":"Moreel","sequence":"first","affiliation":[{"name":"Department of General Internal Medicine, UZ Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Microbiology, Immunology, and Transplantation, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennert","family":"Boeckxstaens","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, UZ Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7526-5001","authenticated-orcid":false,"given":"Albrecht","family":"Betrains","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, UZ Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Microbiology, Immunology, and Transplantation, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Smans","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, UZ Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Molenberghs","sequence":"additional","affiliation":[{"name":"Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), KU Leuven and Hasselt University , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Van Laere","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, UZ Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"De Langhe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, UZ Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Development and Regeneration, KU Leuven , Leuven,","place":["Belgium"]},{"name":"European Reference Network for Immunodeficiency, Autoinflammatory, Autoimmune and Paediatric Rheumatic Disease (ERN-RITA) , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Vanderschueren","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, UZ Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Microbiology, Immunology, and Transplantation, KU Leuven , Leuven,","place":["Belgium"]},{"name":"European Reference Network for Immunodeficiency, Autoinflammatory, Autoimmune and Paediatric Rheumatic Disease (ERN-RITA) , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9783-1780","authenticated-orcid":false,"given":"Daniel","family":"Blockmans","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, UZ Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Microbiology, Immunology, and Transplantation, KU Leuven , Leuven,","place":["Belgium"]},{"name":"European Reference Network for Immunodeficiency, Autoinflammatory, Autoimmune and Paediatric Rheumatic Disease (ERN-RITA) , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"key":"2024121222475709600_keae208-B1","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia rheumatica and giant cell arteritis: a systematic review","volume":"315","author":"Buttgereit","year":"2016","journal-title":"JAMA"},{"key":"2024121222475709600_keae208-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2024121222475709600_keae208-B3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(08)61077-6","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"372","author":"Salvarani","year":"2008","journal-title":"Lancet"},{"key":"2024121222475709600_keae208-B4","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41584-023-00976-8","article-title":"Disease stratification in GCA and PMR: state of the art and future perspectives","volume":"19","author":"Tomelleri","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2024121222475709600_keae208-B5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.semarthrit.2022.152069","article-title":"Concurrent baseline diagnosis of giant cell arteritis and polymyalgia rheumatica\u2014a systematic review and meta-analysis","volume":"56","author":"Nielsen","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2024121222475709600_keae208-B6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MD.0b013e318145275c","article-title":"Development of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica: study of a series of 100 patients","volume":"86","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2007","journal-title":"Medicine (Baltimore"},{"key":"2024121222475709600_keae208-B7","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/rheumatology\/kep395","article-title":"Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study","volume":"49","author":"Mackie","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2024121222475709600_keae208-B8","doi-asserted-by":"crossref","first-page":"152017","DOI":"10.1016\/j.semarthrit.2022.152017","article-title":"Subclinical giant cell arteritis in new onset polymyalgia rheumatica. A systematic review and meta-analysis of individual patient data","volume":"55","author":"Hemmig","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2024121222475709600_keae208-B9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/rheumatology\/kead189","article-title":"Prevalence and characteristics of subclinical giant cell arteritis in polymyalgia rheumatica","volume":"63","author":"De Miguel","year":"2023","journal-title":"Rheumatology"},{"key":"2024121222475709600_keae208-B10","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/ard-2023-224768","article-title":"Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica","volume":"83","author":"De Miguel","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024121222475709600_keae208-B11","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nrrheum.2017.98","article-title":"Visual loss and other cranial ischaemic complications in giant cell arteritis","volume":"13","author":"Soriano","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2024121222475709600_keae208-B12","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.7326\/M23-0679","article-title":"Association between vascular 18F-fluorodeoxyglucose uptake at diagnosis and change in aortic dimensions in giant cell arteritis","volume":"176","author":"Moreel","year":"2023","journal-title":"Ann Intern Med"},{"key":"2024121222475709600_keae208-B13","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.semarthrit.2018.05.007","article-title":"Predictors of positive 18F-FDG PET\/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica","volume":"48","author":"Prieto-Pe\u00f1a","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2024121222475709600_keae208-B14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/art.21699","article-title":"Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients","volume":"55","author":"Blockmans","year":"2006","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024121222475709600_keae208-B15","first-page":"1908","article-title":"Use of 18f-fluorodeoxyglucose positron emission tomography in the diagnosis of polymyalgia rheumatica\u2013a prospective study of 99 patients","volume":"57","author":"Henckaerts","year":"2018","journal-title":"Rheumatol (United Kingdom)"},{"key":"2024121222475709600_keae208-B16","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/rheumatology\/kel376","article-title":"Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients","volume":"46","author":"Blockmans","year":"2007","journal-title":"Rheumatology"},{"key":"2024121222475709600_keae208-B17","doi-asserted-by":"crossref","first-page":"w20512","DOI":"10.4414\/smw.2021.20512","article-title":"18F-FDG PET\/CT compared with ultrasound and biopsy for detection of vasculitis of the temporal artery branches","volume":"151","author":"Rottenburger","year":"2021","journal-title":"Swiss Med Wkly"},{"key":"2024121222475709600_keae208-B18","first-page":"819","article-title":"Diagnostic yield of axillary artery ultrasound in addition to temporal artery ultrasound for the diagnosis of giant cell arteritis","volume":"40","author":"Prearo","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2024121222475709600_keae208-B19","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/mr\/roac058","article-title":"The role of ultrasound and FDG-PET\/CT to detect extracranial artery involvement in patients with suspected large vessel vasculitis","volume":"33","author":"Molina-Collada","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2024121222475709600_keae208-B20","first-page":"772","article-title":"FDG positron emission tomography and ultrasound in the diagnosis of giant cell arteritis: congruent or complementary imaging methods?","volume":"59","author":"Imfeld","year":"2020","journal-title":"Rheumatol (United Kingdom)"},{"key":"2024121222475709600_keae208-B21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10067-021-05819-z","article-title":"Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis","volume":"41","author":"Floris","year":"2022","journal-title":"Clin Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae208\/57180351\/keae208.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/12\/3331\/60903407\/keae208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/12\/3331\/60903407\/keae208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T22:48:27Z","timestamp":1734043707000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/12\/3331\/7636991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":21,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,3,28]]},"published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae208","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,3,28]]}}}